59 results about "Eicosapentanoic acid" patented technology

The subject invention relates to isolated nucleic acid sequences or genes involved in polyketide synthase (PKS) biosynthetic pathways. In particular, such pathways are involved in the production of polyunsaturated fatty acids (PUFAs) such as, for example, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA). Specifically, the invention relates to isolating nucleic acid sequences encoding proteins involved in eukaryotic PUFA-PKS systems and to uses of these genes and encoded proteins in PUFA-PKS systems, in heterologous hosts, for the production of PUFAs such as EPA and DHA.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., "elongases") and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to omega3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, omega6-docosapentaenoic acid or omega3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The subject invention relates to the identification of four genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. Two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The invention relates to a method for enriching n-3 polyunsaturated fatty acid (n-3PUFA) from fish oil, which belongs to the food organism and functional health product technical field. The method takes the fish oil as a raw material, uses the chemical hydrolysis method to hydrolyze the fish oil, respectively obtains high-purity eicosapentaenoic acid (EPA) and high-purity docosahexaenoic acid (DHA) from the hydrolyzed fish oil through separation and purification, uses glycerol and the purified EPA or DHA as raw materials and utilizes lipase to respectively catalyze and synthesize an EPA glyceride product or a DHA glyceride product in an organic phase. The products are mainly n-3PUFA triglyceride; the purity of the products is high; and the concentration of EPA triglyceride in the EPA glyceride is between 90 and 95 percent, and the concentration of DHA triglyceride in the DHA glyceride is between 92 and 94 percent. The high-purity EPA triglyceride product and the high-purity DHA triglyceride product prepared by the method well improve the application pertinence of different health care efficacies of natural fish oil products and improve the functional health care value of the fish oil products.

An orally or parenterally administered composition for reducing the storage of lipids in a human, the composition comprising: an effective amount of hydroxycitric acid; an effective amount of carnitine; an effective amount of biotin; an effective amount of one or more gluconeogenic substrates selected from the group consisting of: aspartate, lactate, glycerol, and a gluconeogenic amino acid or alphaketo analogue thereof; an effective amount of eicosapentanoic acid; and an effective amount of one or more ingredients selected from the group consisting of: medium chain triglycerides (MCT) with fatty acid backbones containing 6 to 14 carbon atoms or their individual fatty acid analogues or metabolic precursors, sesame seeds or derivative products, sesamin and / or its epimer episesamin, caffeine, forskolin, 7-keto dehydroepiandrosterone (7-keto DHEA), green tea extract containing epigallocatechingallate (EGCG), capsaicum, and 5-hydroxytryptophan (5-HTP). The supplement may also be combined with a food, beverage, condiment, spice or salad dressing base to provide a food, beverage, condiment, spice or salad dressing product designed to reduce lipid storage.

The present disclosure relates to antioxidant-stabilized composition containing at least one omega 3 polyunsaturated fatty acid (PUFA). The omega 3 PUFA may include eicosapentanoic acid, docosahexaneoic acid and combinations thereof. The compositions additionally contain an antioxidant package made from a mixture of: at least one form of vitamin E; ascorbyl palmitate; rosemary extract; and grape seed oil. The present disclosure further relates to a method of increasing the oxidative stability of concentrated fish oil.

The invention relates generally to phosphopantetheinyl transferases that are required for activation of a polyketide synthase complex to synthesize long chain poly-unsaturated fatty acids (LC-PUFA's) such as docosahexaenoic acid and eicosapentaenoic acid. In particular, the invention relates to bacterial phosphopantetheinyl transferases, DNA constructs for their expression in host cells, and seed, oil and meal when the host cells comprise a plant. Also provided is a method for making a plant oil containing docosahexaenoic acid and / or eicosapentaenoic acid.

The invention is directed to liquid enteral nutritional compositions comprising a protein fraction comprising more than 25 weight % and up to 80 weight % of a vegetable protein comprising at least a source of pea protein, and a fat fraction comprising (a) 8 to 15 weight % of linoleic acid; (b) 3.0 to 6.0 weight % of a combination of alpha-linolenic acid, docosahexaenoic acid and eicosapentaenoic acid, wherein the amount of ALA is >2.5 weight % and the combined amount of DHA and EPA is ≦2.5 weight %; (c) 10 to 20 weight % of at least one medium-chain fatty acid; and (d) 35 to 79 weight % of at least one mono-unsaturated fatty acid. The compositions provide for a healthy and balanced diet, which is well-tolerated and minimises clinical complications that are frequently associated with the administration of enteral nutrition in patients using tube feeding, especially with respect to a reduced gastric emptying.

A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of eicosapentanoic acid ethyl ester (EPA), of docosahexaenoic acid ethyl ester (DHA), or of a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), especially a mixture of EPA and DHA in an EPA / DHA ratio in the range from about 0.9 to about 1.5 at a dosage of from about 0.7 g to about 6 g per day.

Aquaculture feed compositions having a ratio of concentration of ω-3 polyunsaturated fatty acids of eicosapentaenoic acid [“EPA”; cis-5,8,11,14,17-eicosapentaenoic acid; 20:5] to concentration of docosahexaenoic acid [“DHA”; cis-4,7,10,13,16,19-docosahexaenoic acid; 22:6] greater than 2:1 based on the individual concentrations of EPA and DHA in the aquaculture feed composition are disclosed. Furthermore, such aquaculture feed compositions may have a concentration of the sum of EPA and DHA that is at least about 0.8%, measured as a weight percent of the aquaculture feed composition.

The present invention relates to a method for enhancing levels of polyunsaturated fatty acids in thraustochytrid protists and more particularly to a method of enhancing levels of docosahexaenoic acid and eicosapentaenoic acid in cells of thraustochytrid protist belonging to the genera Schizochytrium, Thraustochytrium and Aplanochytrium deposited at The Microbial Type Culture Collection (MTCC), Institute of Microbial Technology, Chandigarh, India under the accession numbers MTCC 5121, MTCC 5122 and MTCC 5123 respectively by growing the same in a medium with increased viscosity, whereby the cells thus enriched in the said polyunsaturated fatty acids (PUFAs) can then be utilized successfully in various beneficial applications that require polyunsaturated fatty acids, such as in animal feeds, human nutrition and extraction of the PUFAs for nutritional supplementation.

A stable oil containing LC-PUFAs in the form of triacylglycerols, in particular arachidonic acid (ARA), dihomogammalinolenic acid (DHGLA), docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA), may be prepared by direct pressing of one or more biomasses obtained from the culture of a microorganism, especially of a fungus or of a microalga containing the acids ARA, DHGLA, DHA or EPA leading to a first press oil and by bringing a carrier oil entering into the composition of a foodstuff, a cosmetic or pharmaceutical product, into contact with the biomass cake, followed by pressing leading to a second press oil, and then by combining the pressed oils and refining the mixture under controlled conditions.

The invention relates to fish oil and linseed oil soft capsules and a preparation method thereof. The soft capsules mainly comprise the following raw materials in parts by weight: 30 to 80 parts of fish oil, 20 to 60 parts of linseed oil, and 5 to 20 parts of vitamin E; and the fish oil and linseed oil soft capsules are prepared through the steps of preparing an inclusion, making capsule bodies, preparing capsules and the like. Compared with the prior art, the soft capsules have the advantages that the fish oil contains polyunsaturated fatty acids such as docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), so that low-density lipoprotein cholesterol in blood can be effectively reduced, the content of neutral fat is reduced, and high-density lipoprotein cholesterol is increased; and alpha-linolenic acid can promote the discharge of cholesterol, inhibit the synthesis of endogenous cholesterol and raise high-density lipoprotein, so that the effect of reducing blood fat is achieved.

Improved compositions and methods are useful in the treatment and prevention of impulsive, compulsive, reward-seeking, and other addictive behaviors, including applications involving the behavioral / cognitive process of assigning importance, maintaining attention, and assessing salience. The composition includes Vitex agnus-castus (Chastetree berry) extract in an effective amount for supporting and promoting a healthy lifestyle free from addictive behavior or for preventing or treating addictive behavior. The composition also includes garcinia cambogia, aspartic acid, pyruvate, EPA (eicosapentanoic acid), biotin, L-carnitine, and chromium polynicotinate.

The invention concerns a method of sustainably producing an pet food product or product, said method comprising the step of formulating a pet food product by replacing all or part of fish oil in the composition with a single microbial source of eicosapentaenoic acid (“EPA”) and docosahexaenoic acid (“DHA”). In a preferred embodiment, the microbial source comprising DHA and EPA derives from a microorganism / microbe of the genus Schizochytrium or Thraustochytrium.

The present invention relates to the continuous process of sequestration of nutrients from waste effluents released from gas fermentation plants or green-house gases emission managing plants by novel Thraustochytrids. Particularly this invention relates to the methods and systems to enhance sequestration rate and productivity of the process. This invention also relates to rapid biotransformation of nutrients present in waste effluents into high value omega-3 fatty acids like Docosahexaenoic acid (DHA), Docosapentaenoic acid (DPA), Eicosapentaenoic acid (EPA) and lipids for biodiesel. This disclosure is about means of processing of waste streams and producing value added products out of it.

The present invention relates to a cosmetic composition. The composition comprises a cosmetic composition acceptable carrier, the cosmetic composition acceptable carrier comprises an emulsifier, a preservative system and an essence, the composition further comprises omega-3 anti-aging active matters accounting for 1-5% of the total weight of the composition, the omega-3 anti-aging active matters are from extract of deep sea fish oil, and the active matters comprise 15-30 wt% of eicosapentaenoic acid (EPA), 15-30 wt% of docosahexaenoic acid (DHA), 10-20 wt% of gamma-linolenic acid (GLA), 0.5-2wt% of vitamin E acetate and 59.5-18 wt% of isopropyl lauroyl sarcosinate. The cosmetic composition allows active matters to be well absorbed by skins, and can also be used for scalp and hair care.

The invention pertains to the use of a composition in reducing the number of infections episodes and the occurrence of infections in young children, said composition comprising: (a) long chain polyunsaturated fatty acids, wherein the amount of arachidonic acid is less than 0.06 gram per 100 gram fatty acid; and comprising, per 100 g fatty acids: (i) 0.3-0.6 gram docosahexaenoic acid; (ii) 0.2-0.4 gram eicosapentaenoic acid; and (b) between 1.5 and 2.5 gram indigestible oligosaccharides per 100 kcal, comprising: (i) 1.4-2 gram short-chain galactooligosaccharides; and (ii) 0.1-0.5 gram long-chain fructopolysaccharides.

The invention relates to an euphausia superba oil gel capsule and a preparation method thereof, the method comprises the following steps: (1) mixing gelatin, a softener, water and a modifier, heating and uniformly stirring to obtain a gelatin solution, the modifier being a food additive with hydroxyl; and (2) taking gelatin liquid as a capsule wall material, taking euphausia superba oil as a capsule content, and wrapping the capsule content in the capsule wall material to form a soft capsule, thereby obtaining the euphausia superba oil soft capsule. By modifying the capsule wall material, when eicosapentaenoic acid and docosahexaenoic acid in the krill oil are in contact with the inner wall of the soft capsule, hydrophilic carboxyl groups on the eicosapentaenoic acid and docosahexaenoic acid can be combined with hydroxyl groups on the inner wall surface of the soft capsule to form ester groups, and the ester groups are hydrophobic groups; and equivalently, a barrier film layer is formed on the inner wall surface of the soft capsule, so that other krill oil in the capsule can be prevented from continuously contacting with the inner wall surface of the soft capsule, and the problems of hardening and embrittlement of the soft capsule caused by water absorption of the krill oil are well avoided.

The invention provides an apostichopus japonicus and sea cucumber flower lipid extract as well as a preparation method and application thereof. The sea cucumber flower lipid extract mainly contains 20fatty acids such as eicosapentaenoic acid and docosahexaenoic acid and the like, wherein 13 unsaturated fatty acids are contained, and the relative percentage content is not less than 70%. The extracted and purified sea cucumber flower lipid extract is administrated orally, so that the total cholesterol and low-density lipoprotein of hyperlipidaemia rats can be remarkably reduced, and the effectis close to that of a positive control drug atorvastatin calcium tablet. The extracted and purified sea cucumber flower lipid extract has a remarkable effect of reducing triglyceride in serum of the hyperlipidaemia rats, the effect of reducing triglyceride is superior to that of a positive control medicine atorvastatin calcium tablet, and meanwhile, the extracted and purified sea cucumber flower lipid extract has an obvious effect of increasing high-density lipoprotein of the hyperlipidaemia rats. The sea cucumber flower lipid extract has more remarkable blood fat regulating activity than seacucumber flowers, the effect of the sea cucumber flower lipid extract is far better than that of the sea cucumber flowers, and it is prompted that the sea cucumber flower lipid extract can be appliedto research and development of hyperlipidemia regulating drugs or health-care functional foods.

The invention provides a method for purifying unsaturated fatty acids and eicosapentaenoic acid. The method for purifying unsaturated fatty acids includes providing ethylated fish oil, and simulating moving bed chromatography to extract eicosapentaenoic acid contained in ethylated fish oil. The unsaturated fatty acids of pentaenoic acid and docosahexaenoic acid are separated, thereby obtaining high-purity unsaturated fatty acids including eicosapentaenoic acid and docosahexaenoic acid. The method for purifying unsaturated fatty acids of the present invention uses simulated moving bed chromatography to separate unsaturated fatty acids containing eicosapentaenoic acid and docosahexaenoic acid from fish oil, which can not only effectively improve the separation efficiency , and high-purity unsaturated fatty acids containing eicosapentaenoic acid and docosahexaenoic acid can be obtained.

Methods for production of polyunsaturated fatty acids (PUFAs) from coccolithophorid Pleurochrysis carterae are disclosed. This invention provides methods for producing eicosapentaenoic acid (EPA, 20:5 n-3), docosahexaenoic acid (DHA, 22: 6 n-3), stearidonic acid (SDA, 18: 4 n-3), alpha-linolenic acid (ALA, 18: 3 n-3), and oleic acid (18: 1) from Pleurochrysis carterae (Haptophyta, Prymnesiophyceae). The current invention comprises (a). culture conditions for inducing the synthesis of the PUFAs in the said organism; (b). a method to enhance the synthesis of oleic acid in the said organism. ThePUFAs produced with the current invention can be used for food, dietary supplement, cosmetic and pharmaceutical applications.

The invention discloses a giant salamander protein peptide soft capsule. The giant salamander protein peptide soft capsule comprises a capsule shell and contents encapsulated in the capsule shell, andis characterized in that the contents comprise giant salamander oil, perilla oil, rapeseed oil, and salamander protein peptide liquid, and a weight ratio of the giant salamander oil to the perilla oil to the rapeseed oil to the salamander protein peptide liquid is (15-25):(3-8):(3-8):(1-3); and materials of the capsule shell comprise gelatin, glycerin and water, and a weight ratio of the gelatinto the glycerin to the water is (0.8-1.2):(0.3-0.5):(0.8-1.2). The invention also discloses a preparation method of the soft capsule. According to the soft capsule disclosed by the invention, the giant salamander protein polypeptide powder, eicosapentaenoic acid and docosahexaenoic acid in the giant salamander oil and linolenic acid in the perilla oil jointly act on a human body in coordination, so that the soft capsule is easy to dissolve and is absorbed rapidly, has good effects on repairing cells and repairing eyesight, and is convenient for users to carry.

The invention discloses delta 8 desaturase new gene derived from pavlova viridis. Polyunsaturated fatty acids, such as timnodonic acid EPA and docosahexaenoic acid DHA, are important nutrient substances which are necessary for a human body and cannot be synthesized by the human body per se. Aiming at microalgae, namely, pavlova viridis, which can synthesize EPA and DHA naturally, the application adopts conservative district sequence amplification combined with RACE to clone so as to obtain a new delta 8 fatty acid desaturase gene. Due to the obtaining of the gene, basis is provided for further knowing and utilizing an EPA and DHA biosynthesis process which has extremely great practical significance.

The invention discloses a soft fish oil capsule comprising the following raw materials, by weight: 16 to 18 parts of eicosapentaenoic acid, 13 to 15 parts of docosahexaenoic acid, 0.1 to 0.2 part of antioxidant, 20 to 30 parts of grape seed oil, 10 to 20 parts of glycerol, 30 to 40 parts of gelatin, 4 to 6 parts of lemon oil and 6 to 8 parts of span 80. The invention also discloses a preparation method of the soft fish oil capsule. According to the invention, a proper formula is selected and a proper preparation method is matched, so that the oxidation resistance is good.